TD Cowen reiterates Buy on Eli Lilly stock, $1,250 target on approval
TD Cowen reiterated a Buy rating and $1,250 price target on Eli Lilly (LLY) following the approval of its Inluriyo combination therapy. The firm projects 2026 global sales of $290 million, growing to $1.05 billion by 2032. Other analysts, including Berenberg and Guggenheim, also raised their price targets, citing strong growth prospects. Eli Lilly's market cap is $1.04 trillion, with a 55% return over the past year.
How this was made
The 30-second read
Why it matters
The approval adds a high‑margin oncology product to Lilly's pipeline, supporting a bullish price outlook.
Market read
First‑report FDA approval for a large‑cap pharma; likely catalyst for near‑term price appreciation.
What to watch
Pricing negotiations, reimbursement hurdles, and the crowded post‑CDK4/6 landscape could limit upside.
Background
Eli Lilly's Inluriyo combo received FDA clearance, prompting multiple analyst upgrades and a reiterated Buy rating from TD Cowen.
Ticker impact
TD Cowen reiterated a Buy rating and $1,250 price target on Eli Lilly after FDA approval of its Inluriyo combination therapy.
upward pressure, potential breakout above recent resistance
First report of a major FDA approval for a large‑cap pharma; analyst upgrades reinforce bullish outlook.
Market effects
Oncology and CDK4/6 inhibitor space may see increased investor interest.
U.S. biotech sector likely to rally on the news.
Global pharma markets could see competitive pressure as the therapy launches worldwide.
Counterpoint
The approval may not translate into strong sales if competitors launch similar agents or if safety concerns emerge.
Key entities
- companyEli Lilly (LLY)
Pharmaceutical company receiving FDA approval for Inluriyo.
- analyst_firmTD Cowen
Reiterated Buy rating and $1,250 price target on LLY.
